Overview

Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This is a 3-month, randomized, parallel-group study with 2 periods, comparing the efficacy and the safety of rosuvastatin 20 mg versus atorvastatin 80 mg in patients with an acute coronary syndrome (ACS).
Phase:
Phase 4
Details
Lead Sponsor:
Queen's University
Collaborator:
AstraZeneca
Treatments:
Atorvastatin
Atorvastatin Calcium
Rosuvastatin Calcium